Research Paper Volume 11, Issue 18 pp 7780—7795

Figure 1. SIP-SII impairs proliferation and migration and attenuates Akt signaling in bladder cancer cells. (A) Half-maximum inhibitory concentration (IC₅₀) of test drugs evaluated through the MTT viability assay. (B) Cell viability (MTT) assay results for RT112 and JMSU1 cells treated respectively with 2.5 μM or 5μM SIP-SII for the indicated time-points. Cell migration assay results for RT112 cells (C) and JMSU1 cells (D) treated respectively with 2.5 μM or 5.0 μM SIP-SII for 24 h. Representative images at 200x magnification. Data are mean ± SD (error bars) of three experiments performed in triplicate. **P < 0.01 vs. DMSO (control); n = 3. (E) Western blot analysis of total Akt, phospho-Akt, CDK4, Bcl-2, and MMP2 24 h post-exposure to SIP-SII (RT112: 2.5 μM; JMSU1: 5.0 μM).